| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
bniak1
aw D
bniak6
bieta Za
uga2
adny3Departments of 1 Genetics and Pathology, International Hereditary Cancer Center and 2 Dermatology and Venerology, Pomeranian Medical University; 3 III Department of Surgery, Pomeranian Academy of Medicine, Szczecin, Poland; 4 Discipline of Medical Genetics, Faculty of Health, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia; 5 Regional Hospital, Zielona Góra, Poland; 6 Regional Hospital, Gorzow Wielkopolski, Poland
Requests for reprints: Tadeusz D
bniak, Po
abska 4, 70-115 Szczecin, Poland. Phone: 48-91-4661533; Fax: 48-91-4661533; E-mail: debniak{at}wp.pl.
The population frequencies of the CDKN2A variants remain undetermined. In Poland there are three common variants of CDKN2A: an alanine to threonine substitution (A148T), Nt500c>g and Nt540c>t, which have been detected in other populations. To establish if they are associated with an increased malignant melanoma (MM) risk we did an association study based on genotyping 471 patients with MM and 1,210 random control subjects from the same Polish population. We found a significantly increased frequency of the A148T variant among patients with MM (7.0%) in comparison with the general population (2.9%). The incidence of the A148T variant remained greater in both unselected and familial melanoma subgroups. A statistically significant positive association was seen for unselected MM (odds ratio, 2.529; P = 0.0003), especially in patients diagnosed under 50 years of age (odds ratio, 3.4; P = 0.0002). The A148T carrier population (heterozygous G/A alleles) was more likely to have a relative with malignancy compared with the noncarrier population (57% versus 36%, respectively; P = 0.03). Further examination of the CDKN2A promoter sequence done in 20 melanoma patients with the A148T change (heterozygous G/A alleles) and 20 patients with MM without this alteration identified it was in linkage disequilibrium with a polymorphism in the promoter region at position P-493. We found no statistically significant overrepresentation of the Nt500c>g and the Nt540c>t polymorphisms in the Polish melanoma population. In conclusion, the A148T variant of the CDKN2A gene seems to be associated with an increased risk of development of MM. Additional studies are required to confirm whether this particular change is associated with increased risk of other nonmelanoma malignancies.
Key Words: malignant melanoma CDKN2A A148T variant Nt500c>g Nt540c>t P-493
This article has been cited by other articles:
![]() |
J. Healy, H. Belanger, P. Beaulieu, M. Lariviere, D. Labuda, and D. Sinnett Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia Blood, January 15, 2007; 109(2): 683 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kaller, R. Tuominen, A. Ahmadian, V. Magnusson, S. Egyhazi, J. Hansson, and J. Lundeberg Detection of MC1R Polymorphisms with Protease-Mediated Allele-Specific Extension as an Alternative to Direct Sequencing Clin. Chem., December 1, 2005; 51(12): 2388 - 2391. [Full Text] [PDF] |
||||
![]() |
T Debniak, B Gorski, T Huzarski, T Byrski, C Cybulski, A Mackiewicz, S Gozdecka-Grodecka, J Gronwald, E Kowalska, O Haus, et al. A common variant of CDKN2A (p16) predisposes to breast cancer J. Med. Genet., October 1, 2005; 42(10): 763 - 765. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |